Mycobacterium gordonae Follow-up
- Author: Klaus-Dieter Lessnau, MD, FCCP; Chief Editor: Burke A Cunha, MD more...
Further Inpatient Care
- M gordonae infections should be treated until symptoms resolve. Prolonging treatment may prevent relapse, but the optimal treatment duration is unknown. Three, 6, and 12 months of therapy have been used. The improvement of objective abnormalities (eg, chest radiograph findings) may also be useful in determining the optimal duration of treatment. If the treatment time is too short, relapse may occur. If the treatment time is too long, the adverse effects of medication may become a concern.
- Isolation is not indicated (once active tuberculosis infection is excluded); however, the presence of acid-fast organisms on a stain should prompt immediate isolation unless the patient is clearly not acutely contagious.
Further Outpatient Care
- Treat in an outpatient setting. Evaluate the patient monthly for adverse effects.
Inpatient & Outpatient Medications
- At least 2 daily drugs are indicated for documented M gordonae disease. Intermittent therapy has not been evaluated.
Transfer
- Transfer to other facilities is unnecessary. Consultation with an expert from the National Jewish Medical and Research Center in Denver, Colo; Centers for Disease Control and Prevention in Atlanta, Ga; local infectious disease experts; or the department of health may be useful.
Complications
- Dissemination is a concern. Death is an unlikely outcome, except in patients who are immunocompromised.
- Monotherapy may induce resistance.
Prognosis
- With treatment, the reported prognosis of M gordonae infection is excellent.
Patient Education
- Inform patients that they are not infectious and are not dangerous to other people.
Lalande V, Barbut F, Varnerot A, Febvre M, Nesa D, Wadel S, et al. Pseudo-outbreak of Mycobacterium gordonae associated with water from refrigerated fountains. J Hosp Infect. May 2001;48(1):76-9. [Medline].
Yoshida S, Suzuki K, Iwamoto T, Tsuyuguchi K, Tomita M, Okada M, et al. [Detection of molecular epidemiology of Mycobacterium gordonae isolates]. Kekkaku. Jul 2010;85(7):609-14. [Medline].
American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med. Aug 1997;156(2 Pt 2):S1-25. [Medline].
Jun HJ, Jeon K, Um SW, Kwon OJ, Lee NY, Koh WJ. Nontuberculous mycobacteria isolated during the treatment of pulmonary tuberculosis. Respir Med. Dec 2009;103(12):1936-40. [Medline].
Konishi M, Uno K, Kasahara K, Mori K, Yoshimoto E, Maeda K, et al. [A case of pulmonary Mycobacterium gordonae infection progressed for no therapy]. Nihon Kokyuki Gakkai Zasshi. May 2007;45(5):436-40. [Medline].
Lessnau KD, Milanese S, Talavera W. Mycobacterium gordonae: a treatable disease in HIV-positive patients. Chest. Dec 1993;104(6):1779-85. [Medline].
Sneath PH, Mair NS, Sharpe ME, eds. The Mycobacteria. Genus Mycobacterium. In: Bergey's Manual of Systematic Bacteriology. Vol 2. 2nd ed. Baltimore, Md: Williams & Wilkins; 1986:1447.
Sánchez-Morgado JM, Gallagher A, Johnson LK. Mycobacterium gordonae infection in a colony of African clawed frogs (Xenopus tropicalis). Lab Anim. Jul 2009;43(3):300-3. [Medline].
Umeda Y, Matsuno Y, Imaizumi M, Mori Y, Iwata H, Takiya H. Extralobar pulmonary sequestration infected with Mycobacterium gordonae. J Thorac Cardiovasc Surg. Jan 2009;137(1):e23-4. [Medline].
Weinberger M, Berg SL, Feuerstein IM, Pizzo PA, Witebsky FG. Disseminated infection with Mycobacterium gordonae: report of a case and critical review of the literature. Clin Infect Dis. Jun 1992;14(6):1229-39. [Medline].
Print
